We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Sirtuin1 in COVID19 Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04907916
Recruitment Status : Unknown
Verified January 2021 by HHMHamed, Assiut University.
Recruitment status was:  Not yet recruiting
First Posted : June 1, 2021
Last Update Posted : June 1, 2021
Information provided by (Responsible Party):
HHMHamed, Assiut University

Brief Summary:
  1. Evaluate serum level of NAD,Sirtuin1,ADAM17 andPARP1 in covid19 patients
  2. Investigate the correlation between measured biomarkers and each other
  3. Investigate the correlation between measured biomarkers and each other and their correlation with covid19 severity and outcome which may help in the therapy and prevention of disease complication(cytokine storm)

Condition or disease Intervention/treatment
Covid19 Other: SIRTUIN1

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 130 participants
Observational Model: Other
Time Perspective: Other
Official Title: The NAD Dependent Deacetylase Activity of Sirtuin1 in COVID19 Patients
Estimated Study Start Date : June 1, 2021
Estimated Primary Completion Date : August 1, 2022
Estimated Study Completion Date : January 1, 2023

Resource links provided by the National Library of Medicine

Intervention Details:
  • Other: SIRTUIN1
    The NAD dependent deacetylase activity of Sirtuin1

Primary Outcome Measures :
  1. Sirtuin1 in COVID19 [ Time Frame: 1 year ]
    The NAD dependent deacetylase activity of Sirtuin1 in COVID19

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
COVID19 patient with clinical mainfastion with x.ray finding and positive PCR

Inclusion Criteria:

  1. Patient adult age 18years and over(higher incidence) presented to Assiut University Hospital from 1december2020 to 30march.2021(winter2021-second wave)
  2. Suspected of covid19 beacuse of the presence of symptoms suggestive of pneumonia (fever>38) and at least one of the following symptoms ;cough, dyspnea, tachpnea or hypoxia
  3. having undergone RT-PCR (confirmed positive PCR)
  4. Chest CT within 5 days of initial PCR

Exclusion Criteria:

  1. Cases less than 18 years old
  2. Cases express a dissent from the use of their data in the syudy
  3. Cancer patients (affect result of study as they have disrubted level of these biomarker)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04907916

Layout table for location contacts
Contact: Hayam helmy mohamed, master degree 01097635337 hayamhelmy94@gmail.com
Contact: ragaa hamdy mohamed, professor 01063492008 ragaa-2002@yahoo.com

Sponsors and Collaborators
Assiut University
Layout table for additonal information
Responsible Party: HHMHamed, Principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT04907916    
Other Study ID Numbers: SIRTUIN1 in COVID19
First Posted: June 1, 2021    Key Record Dates
Last Update Posted: June 1, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Viral
Respiratory Tract Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases